Abstract

Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.
Lingua originaleEnglish
pagine (da-a)-
Numero di pagine10
RivistaExpert Review of Anticancer Therapy
Volume13
Stato di pubblicazionePublished - 2013

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Therapeutics
Liver Neoplasms
Liver Transplantation
Survival
Health

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cita questo

Treatment of hepatocellular carcinoma: present and future. /.

In: Expert Review of Anticancer Therapy, Vol. 13, 2013, pag. -.

Risultato della ricerca: Article

@article{00d095cf413c47ed821e7e878fd91ca8,
title = "Treatment of hepatocellular carcinoma: present and future.",
abstract = "Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.",
author = "Antonino Giarratano and Calogero Camma' and Giuseppe Brancatelli and Raineri, {Santi Maurizio} and Massimo Galia and Giuseppe Cabibbo and Giuseppe Butera and Chiara Genco and Maida, {Marcello Fabio}",
year = "2013",
language = "English",
volume = "13",
pages = "--",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Treatment of hepatocellular carcinoma: present and future.

AU - Giarratano, Antonino

AU - Camma', Calogero

AU - Brancatelli, Giuseppe

AU - Raineri, Santi Maurizio

AU - Galia, Massimo

AU - Cabibbo, Giuseppe

AU - Butera, Giuseppe

AU - Genco, Chiara

AU - Maida, Marcello Fabio

PY - 2013

Y1 - 2013

N2 - Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.

AB - Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.

UR - http://hdl.handle.net/10447/74498

M3 - Article

VL - 13

SP - -

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

ER -